Slides
Page 1
Corporate Presentation January 2026
Page 2
This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates veligrotug, elegrobart (VRDN- 003), VRDN-006, and VRDN-008, including Viridian's view that the THRIVE and THRIVE-2 data provides support for ongoing elegrobart development; anticipated start dates of studies; anticipated data results and timing of their disclosure, including the anticipated elegrobart topline data from the REVEAL-1 and REVEAL-2 trials and VRDN-008 healthy volunteer clinical data; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including the anticipated approval of the BLA for veligrotug, BLA submission for elegrobart, MAA submission for veligrotug, and IND submission for an anti-TSHR product candidate; the impact of Priority Review, including the potential commercial launch of veligrotug in mid-2026, if approved; clinical trial designs, including the REVEAL-1 and REVEAL-2 global phase 3 clinical trials for elegrobart; the potential utility, efficacy, potency, safety, clinical benefits,clinical response, convenience and number of indications of veligrotug, elegrobart, VRDN-006, VRDN-008 and Viridian’s anti-TSHR product candidate, including Viridian’s view of the strength of the THRIVE durability data and veligrotug’s robust clinical profile; Viridian’s expectations regarding the potential commercialization of veligrotug and elegrobart, if approved, including plans to launch elegrobart with a low-volume autoinjector; Viridian’s ability to receive milestone payments pursuant to the royalty agreement with DRI; the potential for veligrotug and elegrobart to transform the treatment for thyroid eye disease (TED); the potential for veligrotug to be the IV treatment-of-choice for active and chronic TED; potential market sizes and market opportunities for Viridian’s product candidates, including Viridian’s belief that veligrotug is well-positioned to become a leading product in the TED market and its FcRn portfolio has the potential to capture significant market share in autoimmune indications; Viridian’s product candidates potentially being best-in-class; Viridian’s anticipated pipeline expansion; Viridian’s ability to expand to autoimmune disease beyond TED; and Viridian’s expectations regarding its ability to fund its current business through profitability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of Viridian’s product candidates; that results or data from completed or ongoingclinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress, and plans for our ongoing or future research, preclinical and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs, including as a result of a prolonged government shutdown; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from the same; and those risks described from time to time under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. The forward-looking statements in this presentation represent our views as of the date of this presentation. Neither we, nor our affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Trademarks used herein are the property of their respective owners. 2 Cautionary note regarding forward-looking statements
Page 3
3 Viridian aspires to be a leading autoimmune company… … starting with Best in TED In thyroid eye disease (TED), we aim to bring new treatment options to patients that address unmet needs and expand the number of treated patients 3
Page 4
Continue to Advance and Expand Pipeline * Planned; ** If approved. FcRn = neonatal Fc receptor, IGF-1R = insulin-like growth factor-1 receptor, IND = investigational new drug application, POC = proof of concept, TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor. 4 Viridian is building towards a leadership position in TED enabling our expansion to other autoimmune diseases 2 Yrs 5 YrsCommercial Company Revenue Funded Growth 2026 TSHR POC* FcRn POC* New Pipeline INDs and POCs* Veli Launch** FcRn Expansion* TSHR IND* 003 Launch** 003 Topline* IGF-1R TED Autoimmune Thyroid
Page 5
Primed for new entrants and growth • Low penetration with currently approved product • No subcutaneous option available commercially • Recent WW approvals is expanding the global market • New-start market dynamic • Limited competitive development landscape with high bar set by IGF-1R inhibitors Current TED Market ~$2B1 Annualized TED market Source: 1Annualized TEPEZZA sales based on Amgen Q4 2024 Earnings, 2 Amgen Press Release “TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE,” 3 Amgen Press Release “AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY,” 4 Amgen Press Release “AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS,” 5 Amgen Press Release “Amgen’s TEPEZZA®▼ (teprotumumab) granted marketing authorisation as the first targeted treatment specifically for adults with moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom,” 6 Viridian THRIVE data on file, 7 Viridian THRIVE-2 data on file, 8 Planned product profile, including planned clinical dosing regimen. BLA = Biologics License Application, IGF-1R = insulin-like growth factor-1 receptor, IND = investigational new drug, IV = intravenous, TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor, SC = subcutaneous, WW = worldwide. 5 Viridian is building a portfolio to address patient needs in TED with veligrotug, elegrobart (VRDN-003), and targeted pipeline expansion Veligrotug v Compelling profile with potential to be IV treatment of choice Subcutaneous and potential best-in-class therapy in TED Elegrobart (VRDN-003) TSHR Inhibitor & Pipeline • Transformative convenience of at-home autoinjector every 4 or 8 weeks8 • Shares same binding domain as veligrotug • Potential to greatly expand TED market, if approved • Pivotal readouts in Q1 2026 for active TED REVEAL-1 study, and Q2 2026 for chronic TED REVEAL-2 • Only remaining autoinjector SC product in phase 3 development for TED Innovate for the future of TED • PDUFA target: June 30, 2026 • Robust and consistent clinical responses in active and chronic TED6,7 • Rapid onset of treatment effect6,7 • First statistically significant demonstration of diplopia resolution and response in a global chronic TED phase 3 study7 • Generally well-tolerated6,7 • 12-week treatment course • TSHR product candidate designed to be best-in-class: half-life extension to support extended dosing intervals in an autoinjector • Potential in TED and Graves • Anticipated IND Q4 2026 • Evaluating novel treatments for the future of TED
Page 6
BLA = biologics license application, FcRn = neonatal Fc receptor, IND = investigational new drug application, KOL = key opinion leader, TED = thyroid eye disease. Viridian has a proven track record of execution 1 $900 BLA submitted during the US government shutdown Secured access to up to ~$900M in capital in 2025, supporting funding of current business plans through profitability 8 2 8 phase 3 TED clinical trials conducted across veligrotug and elegrobart Advanced FcRn portfolio: 2 INDs submitted in two years 1200 2 >1200 TED patients enrolled in Viridian clinical trials since January 2024 Granted 2 veligrotug regulatory designations in 2025: Priority Review, Breakthrough Therapy 6
Page 7
DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Anticipated Milestones Thyroid Eye Disease Portfolio Veligrotug Anti-IGF-1R; Intravenous Elegrobart (VRDN-003) Anti-IGF-1R; Subcutaneous Anti-TSHR Subcutaneous FcRn- Targeting Autoimmune Portfolio VRDN-006 FcRn-targeting Fc fragment VRDN-008 Bispecific, extended half-life FcRn inhibitor BLA = Biologics License Application, Fc = fragment crystallizable, FcRn= neonatal Fc receptor, HV = healthy volunteer, IGF-1R = insulin-like growth factor-1 receptor, IND = Investigational New Drug, TED = thyroid eye disease, TSHR = thyroid-stimulating hormone receptor, YE = year-end, IgG = immunoglobulin G. 7 Strong and expanded TED portfolio and continued progress across FcRn inhibitors Communicate dev plan in 2026 HV data 2H 2026 Topline data in Q1 and Q2 2026 PDUFA target date June 30, 2026 IND Q4 2026Potential in TED and Graves
Page 8
Veligrotug Intravenous Elegrobart (VRDN-003) Subcutaneous Anti-TSHR Subcutaneous FcRn inhibitor portfolio Subcutaneous BLA = Biologics License Application, FcRn = neonatal Fc receptor, HV = healthy volunteers, IND = investigational new drug application, IV = intravenous, MAA = Marketing Authorisation Application, NHP = non-human primate, PDUFA = Prescription Drug User Fee Act, TED = thyroid eye disease, TSHR = thyroid-stimulating hormone receptor. Veligrotug PDUFA date of June 30th and multiple additional anticipated value-creating catalysts portfolio-wide in 2026 20262025 MAA Submission Q1 2026 PDUFA target June 30, 2026 REVEAL-1 Topline Q1 2026 REVEAL-2 Topline Q2 2026 IND Q4 2026 Strong balance sheet: $888M cash as of Oct 31, 2025; cash, near-term DRI milestones, and anticipated future revenues, if both veligrotug and VRDN-003 are approved, are expected to fund Viridian’s current business plans through profitability BLA Accepted Dec 2025 ✓ VRDN-008 HV Data: 2H 2026 VRDN-008 IND Submitted Dec 2025 ✓ 8
Page 9
9 Veligrotug Intravenous anti–IGF-1R
Page 10
Sources: 1 George A et al. Front Endocrinol (Lausanne). 2021;11:629925., 2 Smith TJ et al. NEJM. 2016;375(16):1552–1565., 3 Bahn RS. NEJM. 2010; 362(8): 726–738., 4 Bartley GB et al. Am J Ophthalmol 1996;121(3):284–290., 5 Viridian-sponsored market research, includes active and chronic TED. TED patient images are from Bahn RS. NEJM. 2010; 362(8): 726–738. Copyright © (2010) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. IGF-1R = insulin-like growth factor-1 receptor, TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor. 10 TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes Normal Eye Anatomy Bulging Eyes Enlargement of extraocular muscles Optic Nerve Autoantibodies trigger IGF-1R/TSHR pathway1 Heterogeneous autoimmune disease with clinical signs and symptoms that can vary or modulate following onset, in some cases for the rest of a patient’s life2,3 Main signs include proptosis (eye bulging), redness, swelling, diplopia (double vision), and lid retraction2,3 Severe cases can cause sight-threatening optic nerve compression4 An estimated 190K people in the US alone have moderate to severe TED5 People living with TED experience proptosis, redness, swelling, diplopia, and lid retraction Thyroid Eye Disease (TED)
Page 11
CHRONIC TED Key Inclusion Criteria • Proptosis of ≥3 mm • Any CAS (0-7) • Onset of TED symptoms >15 months Trial Design • N = approx. 159 (actual enrollment: 188 patients) • 15-week primary endpoint, 52-week total follow-up • Double-masked, randomized, placebo-controlled ACTIVE TED Key Inclusion Criteria • Proptosis of ≥3 mm • CAS ≥3 • Onset of TED symptoms within 15 months Trial Design • N = 90 (actual enrollment: 113 patients) • 15-week primary endpoint, 52-week total follow-up • Double-masked, randomized, placebo-controlled 11 Source: Viridian THRIVE and THRIVE-2 data on file. CAS = clinical activity score, mm = millimeter, TED = thyroid eye disease, PDUFA = Prescription Drug User Fee Act. Veligrotug granted Priority Review by the US FDA, with PDUFA target date of June 30, 2026 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints Veligrotug met the primary and all secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2
Page 12
Achieved the primary and all secondary endpoints with high level of statistical significance (p < 0.0001) Source: Viridian THRIVE week 15 topline data on file (interim topline database lock) & week 52 data on file (final database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor, SAE = serious adverse event, TED = thyroid eye disease. 12 THRIVE: Veligrotug showed robust and consistent clinical activity in active TED patients Rapid onset of treatment effect in as few as 3 weeks Generally well-tolerated, with no treatment-related SAEs and low (5.5%) placebo-adjusted rate of hearing impairment AEs at week 15; consistent safety profile through week 52 Demonstrated strong durability of proptosis response: 70% of topline proptosis responders maintained response at week 52 (Active TED) Detailed data can be found in appendix starting on slide 30
Page 13
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, TED = thyroid eye disease. 13 THRIVE-2: Demonstrated robust and consistent clinical activity in the largest and broadest TED phase 3 study completed to date Achieved the primary and all secondary endpoints with statistical significance in largest IV IGF-1R antibody study in TED to date Rapid onset of treatment effect, with statistically significant proptosis response in as few as 3 weeks First pivotal phase 3 study to demonstrate statistically significant diplopia response & resolution in chronic TED Generally well-tolerated, with low (9.6%) placebo- adjusted rate of hearing impairment AEs (Chronic TED) Detailed data can be found in appendix starting on slide 40
Page 14
Sources: 1 Viridian THRIVE data on file, 2 Viridian THRIVE-2 data on file. AE = adverse event, BLA = Biologic License Application, CAS = clinical activity score, IV = intravenous, TED = thyroid eye disease. 14 Veligrotug is well-positioned to become the treatment-of-choice for active & chronic TED Active & chronic data in BLA submission Supported by one of the largest & broadest TED pivotal programs to date1,2 Generally well-tolerated Low rate of hearing impairment AEs1,2 Rapid onset of treatment effect Significant proptosis response demonstrated in as few as 3 weeks1,2 Significantly reduced treatment burden ~70% shorter infusion time and shorter course of therapy1,2 Robust clinical responses across all primary & secondary endpoints Consistent reductions in proptosis, diplopia, and CAS in both active & chronic TED1,2 Significant clinical activity on diplopia resolution & response First pivotal phase 3 study to demonstrate statistically significant impact on diplopia in chronic TED2
Page 15
• Narrow and well-defined call point supports small, efficient sales force • Estimated ~2,000 core prescribers in the U.S.7 • Tepro launched with field force of <100 sales reps8 • Established market price and reimbursement pathway • Current WAC price for tepro: ~$500K per complete treatment course in the U.S.9 • Established strong & deep KOL relationships • Investigators have experience with veligrotug, one of the largest TED clinical program to date 15 Sources: 1 Annualized teprotumumab sales based on Amgen Q4 2024 earnings, 2 Horizon 2Q 2020 and full-year 2020 earnings, 3 TEPEZZA® (teprotumumab-trbw) Patient Website, 4 Viridian-sponsored market research, includes active and chronic TED, 5 Amgen Q3 2025 earnings, 6 Viridian data on file, 7 Viridian internal claims analysis on file, 8 FiercePharma, “Horizon bulks up sales force ahead of $750M inflammatory eye drug launch,” published: June 25, 2019, 9 Internal estimate, based on 80 kg patient. KOL = key opinion leader, TED = thyroid eye disease, Tepro = teprotumumab, WAC = wholesale acquisition cost. Veligrotug’s robust clinical profile expected to drive rapid commercial adoption in TED, if approved Veligrotug is well-positioned to become the leading product in the new-start TED market • ~$2B single-product market in U.S.1 • Tepro launch as first entrant: $166M net sales in first full quarter of launch (2Q 2020), and $820M in launch year2 • Only an estimated ~25k patients treated to date among estimated US prevalence of ~190K moderate to severe TED3,4,5 • New-start market dynamic enables potential rapid uptake for new entrant • Strong patient demand for new options • >1200 TED patients enrolled in Viridian clinical trials since January 20246 Large & Growing Market Focused Footprint
Page 16
16 Viridian’s launch preparation prioritizes strong external stakeholder relationships and focus on patients Field Medical Leadership in place, >500 KOL and HCP engagements in Q4 2025 Field Sales Leadership in place, actively staffing top launch-ready talent Market Access Leadership in place, active payer engagements ongoing Patient Services Leadership in place, infrastructure build underway Preparing for June 30, 2026 PDUFA target date with Priority Review Launch to focus on ~2,000 core prescribers, if approved Launch preparations are well underway with experienced leadership teams in place Viridian’s go-to-market approach built on a foundational understanding of the TED market driven by robust Physician, Patient, and Payer market research TED = thyroid eye disease, KOL = key opinion leader, HCP = healthcare provider, PDUFA = Prescription Drug User Fee Act
Page 17
17 Elegrobart (VRDN-003) Subcutaneous half-life extended anti–IGF-1R
Page 18
TED = thyroid eye disease. 18 Positive phase 3 data for veligrotug in active and chronic TED support ongoing elegrobart development Veligrotug Elegrobart Half-life extension technology Fully enrolled. Topline data release expected: REVEAL-1: Q1 2026; REVEAL-2: Q2 2026 v THRIVE & REVEAL clinical programs share key features and operations Veligrotug & elegrobart share the same binding domain Robust and consistent clinical responses across active and chronic TED
Page 19
• Doubled market size after SC launch1 IV Drug SC Drug CD38 IV Launch: Nov 2015 by J&J for multiple myeloma SC Launch: May 2020 by J&J • 30% of new scripts converted in 3 years2 IV Drug SC Drug CD20 IV Launch: Mar 2017 by Roche for MS SC Launch: Aug 2020 by Novartis • Doubled combined CD20 market size after Kesimpta launch3,4 19 Third party trademarks used are the property of their respective owners. Sources: 1 https://www.fiercepharma.com/pharma/jjs-switch-iv-subcutaneous-darzalex-85-complete-us, 2. Novartis 2022 Q4 results, 3 Roche Earnings, 4 Novartis Q3 2023 Earnings. CD20 = cluster of differentiation 20 protein, CD38 = clusterof differentiation38 protein, IV = intravenous, IGF-1R = insulin-like growth factor-1 receptor, MS = multiple sclerosis, SC = subcutaneous. Later-entrant SC therapies have demonstrated ability to expand the market and take market share from incumbent IV Significant potential opportunity for a best-in-class, long half-life and convenient subcutaneous anti–IGF-1R IV to SC with same molecule IV to SC with new SC entrant • 85% of IV market converted in 2 years1
Page 20
20 Source: 1 Teprotumumab Prescribing Information, 2 Planned product profile, including planned clinical dosing regimen. IGF-1R = insulin-like growth factor-1 receptor,IV = intravenous, Q4W = every 4 weeks, Q8W = every 8 weeks, SC = subcutaneous. Elegrobart designed to bring a potentially best-in-class therapy for patients Potential for reduced treatment burden to patients 6 SC Treatments Self-administered every 4 weeks 1 loading dose + 5 Q4W 3 SC Treatments Self-administered every 8 weeks + + 1 loading dose + 2 Q8W Easy self-administration transforms patient convenience Infrequent administration & low volume Flexibility for at-homeadministration Relieves infusion burden while potentially preserving anti–IGF-1R efficacy Lower drug exposure potentially improves safety Teprotumumab IV 1 8 INFUSIONS administered every 3 weeks Elegrobart Autoinjector Phase 3 pivotal program is evaluating two dosing regimens: 60–90 min infusions = ~8–12 hours in an infusion chair + + + + + + + Potential Elegrobart Benefits2 + + + + +
Page 21
Subcutaneous Elegrobart Pharmacokinetic (PK) Modeling Elegrobart development expected to proceed along its own clinical development path regarding dosing regimens and safety profile. PK modeling used a 2-compartment model, loading dose of 600 mg, and subsequent doses of 300 mg/doses at specified intervals for 24 weeks. Veligrotug PK modeling assumed 5 infusions, based on PK data from the two-infusion phase 2 TED study. Source: Viridian’s phase 2 multiple ascending dose study - clinical data and modeling on file. IV = intravenous, PK = pharmacokinetics, Q4W = every four weeks,Q8W = every eight weeks, SC = subcutaneous, TED = thyroid eye disease, wks = weeks. 21 PK model shows Q4W and Q8W dosing of elegrobart SC achieves predicted exposure levels of veligrotug at 3-10 mg/kg • Veligrotug exposures modeled from a phase 2 TED clinical trial inform the exposure ranges anticipated to produce clinical benefit – Two infusions of 3 and 10 mg/kg veligrotug IV, dosed three weeks apart, each showed robust clinical activity in a phase 2 TED clinical trial • Models of subcutaneous elegrobart Q4W and Q8W achieve the range of veligrotug exposures that showed robust clinical activity in a two- infusion phase 2 TED study – Elegrobart and veligrotug have the same binding domain • Both proposed elegrobart dosing regimens – Q4W & Q8W – present potential for transformative options for TED patients 0 10 20 0 25 50 75 100 Concentration (μg/mL) 003 Q8W 24 wks 003 Q4W 24 wks 3 mg/kg IV exposure range (Cmin to Cavg) 10 mg/kg IV exposure range (Cmin to Cavg) weeks
Page 22
22 CAS = clinical activity score, mm = millimeter, TED = thyroid eye disease. Enrollment complete in ongoing phase 3 clinical trials for elegrobart REVEAL trials expected to deliver topline results in Q1 2026 and Q2 2026, respectively CHRONIC TED Key Inclusion Criteria • Proptosis of ≥3 mm • Any CAS (0–7) • Onset of TED symptoms >15 months Trial Design • N = 195 (actual enrollment: 204 patients) • 24-week primary endpoint, 52-week total follow-up • Double-masked, parallel-group, placebo-controlled ACTIVE TED Key Inclusion Criteria • Proptosis of ≥3 mm • CAS ≥3 • Onset of TED symptoms within 15 months Trial Design • N = 117 (actual enrollment: 132 patients) • 24-week primary endpoint, 52-week total follow-up • Double-masked, parallel-group, placebo-controlled Patients without response at 24 weeks may receive open-label elegrobart
Page 23
1 600 mg loading dose given as two 300 mg injections. 2 Placebo injections administered at alternating study visits to maintain study blinding across arms. D = day, Q4W = every 4 weeks, Q8W = every 8 weeks, W = week. 23 REVEAL-1 & REVEAL-2 will evaluate Q4W and Q8W active arms of elegrobart versus placebo Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) Elegrobart (Every 4 Weeks)1 D11 W4 W8 W12 W16 W20 Elegrobart (Every 8 Weeks)1, 2 Placebo Key: Elegrobart 300 mg Placebo W24Treatment Arms (1:1:1) Through W52 Additional efficacy & safety follow-up through week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: • Proptosis change • Clinical Activity Score (CAS) • Diplopia (double vision) Primary Endpoint Analysis
Page 24
24 FcRn Inhibitor Portfolio
Page 25
Pathogenic autoantibodies cause inflammation and damage to healthy tissues and cells, driving the pathology of autoimmune diseases1 Serum levels of pathogenic autoantibodies are maintained, in part, by FcRn-mediated recycling1 FcRn inhibition reduces pathogenic autoantibody levels1, with demonstrated efficacy and safety in patients with gMG, CIDP, and ITP2 Source: 1 Pyzik M et al.Nat Rev Immunol. 2023;23:415–432, 2 Vyvgart Prescribing Information. CIDP = chronic inflammatory demyelinating polyneuropathy, FcRn = neonatal Fc receptor, gMG = generalized myasthenia gravis, IgG = immunoglobulin G, ITP = primary immune thrombocytopenia. 25 Pathogenic autoantibodies drive disease pathophysiology in a number of autoimmune diseases FcRn-Mediated Recycling of IgGs, Including Pathogenic Autoantibodies1 1 2 3 4 IgGs, including pathogenic autoantibodies, enter the cell1 IgGs and pathogenic autoantibodies bind to FcRns2 Unbound antibodies are degraded by the lysosome3 FcRn-bound IgGs, including pathogenic autoantibodies, are recycled4 IgG Degraded antibody FcRn Endosome Lysosome
Page 26
Source: 1 Pyzik M et al.Nat Rev Immunol. 2023;23:415–432. Fc = fragment crystallizable, FcRn = neonatal Fc receptor, IgG = immunoglobulin G. 26 Viridian’s portfolio of FcRn inhibitors aims to reduce circulating levels of pathogenic autoantibodies by blocking FcRn Fc fragment that blocks IgG from binding to FcRn Binds to albumin and FcRn for a more sustained reduction of pathogenic autoantibodies Fc fragment Fc fragment FcRn inhibitor and IgGs, including pathogenic autoantibodies, enter the cell1 FcRn inhibitor blocks IgGs from binding to FcRn2 Unbound IgGs, including pathogenic autoantibodies, are degraded by the lysosome, reducing serum levels3 The bound FcRn inhibitor and IgG are recycled and released4 1 2 3 4 VRDN-006 VRDN-008 Albumin binding domain Inhibition of FcRn Reduces IgGs, Including Pathogenic Autoantibodies1 FcRn Inhibitor IgG Degraded antibody FcRn Endosome Lysosome
Page 27
Projected WW MG and CIDP FcRn Market1 Source: 1 2024 actuals calculated from argenx (Vyvgart + Vyvgart Hytrulo), Zai Labs (Vyvgart), and UCB (Rystiggo) annual reported earnings; 2030 estimates based on Evaluate Pharma data for Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy, batoclimab, and IMVT-1402, accessed July 2025. CIDP = chronic inflammatory demyelinating polyneuropathy, FcRn = neonatal Fc receptor, MG = myasthenia gravis, WW = worldwide. 27 FcRn inhibitors are a large market opportunity; market size of MG and CIDP alone are projected to be over $11B by 2030 ...with Potential in Additional Autoimmune Indications Sjogren’s Syndrome Lupus Nephritis Myositis Graves’ Disease 2024 2030 $11.2B $2.5B
Page 28
Fc = fragment crystallizable, FcRn = neonatal Fc receptor, FIH = first in human, IgG = immunoglobulin G, IND = Investigational New Drug, LDL = low-density lipoprotein, NHP = non-human primate, YE = year-end. 28 Viridian’s FcRn portfolio has the potential to capture significant market share in autoimmune indications VRDN-006 VRDN-008 v v IgG Suppression • IgG reduction data consistent with the FcRn inhibitor class • Deeper and more sustained reduction of IgG vs. efgartigimod in NHPs Dosing • Targeting patient self-administration in a convenient subcutaneous injection • Targeting a less frequent, self-administered, subcutaneous injection Safety • Spared albumin and LDL in healthy volunteers, generally well-tolerated • Expect to maintain the Fc fragment safety profile Half-life Extended Bispecific FcRn InhibitorHighly Selective Fc Fragment and FcRn Inhibitor
Page 29
Appendix 1) THRIVE in Active TED Pivotal Data 2) THRIVE-2 in Chronic TED Pivotal Data 3) Elegrobart (VRDN-003) Phase 1 Data 4) FcRn Non-Human Primate Data 29
Page 30
30 THRIVE in Active TED Global phase 3 clinical trial pivotal data
Page 31
D = day, mm = millimeter, TED = thyroid eye disease, W = week. 31 THRIVE is a phase 3 randomized, controlled, double-masked trial of veligrotug in active TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 75 D1 W3 W6 W9 W12 Placebo n = 38 Key: Veligrotug 10 mg/kg Placebo W15Treatment Arms (2:1 randomization) Through W52 Additional efficacy & safety follow-up at: • Week 24 • Week 36 • Week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: • Proptosis mean change from baseline • Diplopia (double vision) • Clinical Activity Score (CAS) Primary Endpoint Analysis Final THRIVE readout at Week 52 Key Inclusion Criteria • CAS ≥3 • Onset of TED symptoms within 15 months • Proptosis of ≥3 mm
Page 32
7.8 Veligrotug (n = 75) Placebo (n = 38) Participant Demographics Age in years, mean (SD) 48.9 (12.4) 49.1 (12.5) Female sex, n (%) 56 (75%) 31 (82%) White race, n (%) 51 (68%) 19 (50%) Disease Characteristics Months since TED onset, mean (SD) 7.9 (3.7) 7.2 (3.8) Baseline proptosis by exophthalmometry (mm), mean (SD) 23.2 (3.1) 23.2 (3.3) Baseline CAS, mean (SD) 4.5 (1.0) 4.8 (1.1) Participants with diplopia, n (%) 50 (67%) 26 (68%) Diplopia (Gorman Score), mean (SD)1 2.0 (0.8) 2.0 (0.7) Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis are based on study eye (defined as eye with greater proptosis at baseline). 1 Of patients with diplopia at baseline. CAS = clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. 32 THRIVE baseline characteristics were well-balanced between active and placebo arms
Page 33
Veligrotug (n=75) Placebo (n=38) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 70% 5% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.89 mm -0.48 mm p < 0.0001 Diplopia Diplopia complete resolution2 54% 12% p < 0.0001 Diplopia responder rate3 63% 20% p < 0.0001 CAS Clinical activity score (CAS) 0 or 1 64% 18% p < 0.0001 CAS mean change from baseline -3.4 -1.7 p < 0.0001 Overall Response Overall responder rate (ORR)4 67% 5% p < 0.0001 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 Percentage of participants with ≥2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥2 mm increase), 2 Percentage of participants with baseline diplopia (Gorman Score >0) and a score of 0 at Week 15, 3 Percentage of participants achieving a reduction of at least 1 on the Gorman subjective diplopia scale at week 15, among patients with diplopia at baseline, 4 Percentage of participants with ≥2 mm reduction in proptosis AND ≥2-point reduction in CAS from baseline in the study eye, without corresponding deterioration [≥2 mm/point increase] in proptosis or CAS in the fellow eye. CAS = clinical activity score. 33 THRIVE achieved high level of statistical significance across all primary and secondary endpoints at 15 weeks
Page 34
0 20 40 60 80 100 34 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. mm = millimeter, PBO = placebo. Primary endpoint of proptosis responder rate met at 15 weeks: 70% for patients receiving veligrotug compared with 5% on PBO 53% of patients receiving veligrotug achieved a proptosis response at 3 weeks, after just 1 infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline Proptosis Responder Rate (%)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 -0.51 -0.67 -0.71 -0.72 -0.48 -1.82 -2.39 -2.66 -2.76 -2.89 -4 -3 -2 -1 0 Proptosis Mean Reduction (mm)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 11% 53% 11% 64% 13% 64% 13% 72% 5% 70% Analysis Visits Placebo Veligrotug Analysis Visits Placebo Veligrotug
Page 35
0 20 40 60 80 100 0 20 40 60 80 100 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. CAS = clinical activity score. 35 Majority of patients receiving veligrotug had complete resolution of diplopia and minimal disease activity (CAS) at week 15 Diplopia Complete Resolution CAS Score 0 or 1 Analysis Visits Diplopia Resolution Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Placebo Veligrotug 4% 26% 12% 32% 12% 35% 12% 44% 12% 54% Diplopia Responder Rate at Week 15 63% 20% Diplopia Responder Rate at Week 15 7% 30% 25% 46% 24% 53% 20% 64% 18% 64% Analysis Visits CAS 0 or 1 Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Placebo Veligrotug
Page 36
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). CT = computed tomography, IGF-1R = insulin-like growth factor-1 receptor, mm = millimeter, MRI = magnetic resonance imaging. 36 THRIVE demonstrated consistency between Hertel and MRI / CT and validates both as reliable tools for measurements of proptosis Veligrotug (n=75) Placebo (n=38) Proptosis responder rate at week 15 70% 5% Proptosis mean change from baseline at week 15 -2.89 mm -0.48 mm Veligrotug (n=75) Placebo (n=38) Proptosis responder rate at week 15 69% 9% Proptosis mean change from baseline at week 15 -2.91 mm -0.58 mm Hertel Exophthalmometry MRI / CT
Page 37
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 6 unrelated SAEs in 4 participants: cellulitis, appendicitis, dyspnoea, hyperthyroidism, aortic dissection (planned surgery for known Type B aortic dissection), depression (diagnosed prior to 1st dose); Includes multiple terms aggregated using standard sets of MedDRA terms. AE = adverse event, MedDRA= medical dictionary for regulatory activities, SAE = serious adverse event, TEAE = treatment-emergent adverse event. 37 Veligrotug was generally well-tolerated at week 15, with no treatment-related SAEs, and 96% of veligrotug-treated patients completed all doses Veligrotug N=75 n (%) Placebo N=38 n (%) Participants with any treatment-emergent adverse event (TEAE) 66 (88%) 24 (63%) Participants with any serious AE (SAE) 4 (5%)1 0 Participants with any treatment-related TEAE 53 (71%) 9 (24%) Participants with any treatment-related SAE 0 0 • Vast majority of TEAEs in both arms were mild • Low treatment discontinuation rate ‒ 4% in veligrotug arm • No treatment-related SAEs
Page 38
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 Includes multiple terms aggregated using standard sets of MedDRA terms, 2 Reported as percentage of menstruating women. AE = adverse event, MedDRA = medical dictionary for regulatory activities. 38 Veligrotug was generally well-tolerated at week 15, with a 5.5% placebo-adjusted rate of hearing impairment AEs AEs occurring at ≥10% frequency in either arm Veligrotug N=75 n (%) Placebo N=38 n (%) Muscle spasms 32 (43%) 2 (5%) Headache 16 (21%) 5 (13%) Infusion related reaction (IRR) 13 (17%) 1 (3%) Hearing impairment1 12 (16%) 4 (11%) Hyperglycemia1 11 (15%) 2 (5%) Fatigue1 10 (13%) 6 (16%) Nausea 10 (13%) 3 (8%) Ear discomfort 9 (12%) 1 (3%) Diarrhea 8 (11%) 1 (3%) Alopecia 6 (8%) 4 (11%) Menstrual disorders1,2 8 / 34 (24%) 1 / 12 (8%)
Page 39
Source: Viridian THRIVE week 52 data on file (final database lock). 1 Responders at week 15 who still had at least a 2-millimeter (mm) reduction in proptosis compared to baseline at week 52, without worsening in the fellow eye (≥2 mm increase), as measured by exophthalmometry. Definition of durability is the same as that used for teprotumumab durability as reported in its U.S. Prescribing Information. • No changes to veli’s safety profile during the follow-up period • Vast majority of adverse events reported at topline resolved by Week 52 39 70% of proptosis responders in THRIVE maintained response at Week 52 in long-term follow up Proptosis Durability 70% (21/30 participants) of Week 15 proptosis responders maintained a proptosis response at Week 521 Safety Resolution
Page 40
40 THRIVE-2 in Chronic TED Global phase 3 clinical trial pivotal data
Page 41
D = day, mm = millimeter, TED = thyroid eye disease, W = week. 41 THRIVE-2 is a phase 3 randomized, controlled, double-masked trial of veligrotug in chronic TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 125 D1 W3 W6 W9 W12 Placebo n = 63 Key: Veligrotug 10 mg/kg Placebo W15Treatment Arms (2:1 randomization) Through W52 Additional efficacy & safety follow-up at: • Week 24 • Week 36 • Week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: • Proptosis mean change from baseline • Diplopia (double vision) • Clinical Activity Score (CAS) Primary Endpoint Analysis Final THRIVE-2 readout at Week 52 Key Inclusion Criteria • Any CAS (0–7) • Onset of TED symptoms >15 months • Proptosis of ≥3 mm
Page 42
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis are based on study eye (defined as eye with greater proptosis at baseline). 1 Of participants with diplopia at baseline. CAS = clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. 42 THRIVE-2 baseline characteristics were well-balanced between active and placebo arms Veligrotug (n = 125) Placebo (n = 63) Participant Demographics Age in years, mean (SD) 50.5 (13.5) 50.7 (12.0) Female sex, n (%) 95 (76%) 46 (73%) White race, n (%) 94 (75%) 48 (76%) Disease Characteristics Months since TED onset, mean (SD) 69.8 (78.9) 81.7 (83.7) Baseline proptosis by exophthalmometry (mm), mean (SD) 24.3 (3.3) 23.8 (3.3) Baseline CAS, mean (SD) 2.7 (1.9) 2.5 (1.8) Baseline CAS 0 or 1, n (%) 44 (35%) 22 (35%) Baseline CAS ≥ 3, n (%) 71 (57%) 33 (52%) Participants with diplopia, n (%) 65 (52%) 37 (59%) Diplopia (Gorman Score), mean (SD)1 2.0 (0.8) 2.1 (0.9)
Page 43
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). 1 Percentage of participants with ≥2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥2 mm increase), 2 Percentage of participants achieving a reduction of at least 1 on the Gorman subjective diplopia scale, among patients with diplopia at baseline (n=102 participants), 3 Percentage of participants with baseline diplopia (Gorman Score >0; n=102 participants) and a score of 0 at the analysis timepoint, 4 Percentage of participants with ≥2 mm reduction in proptosis AND no worsening in CAS from baseline in the study eye, without corresponding deterioration (≥2 mm/point increase) in proptosis or CAS in the fellow eye, 5 Of participants with CAS ≥3 at baseline (n=104 participants); CAS subpopulation analyses were prespecified, exploratory endpoints and statistical p values are for descriptive purposes only. CAS = clinical activity score. 43 THRIVE-2 met all primary and secondary endpoints at 15 weeks Veligrotug (n=125) Placebo (n=63) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 56% 8% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.34 mm -0.46 mm p < 0.0001 Diplopia Diplopia responder rate2 56% 25% p = 0.0006 Diplopia complete resolution3 32% 14% p = 0.0152 Overall Response Overall responder rate (ORR)4 56% 7% p < 0.0001 CAS5 (prespecified exploratory endpoints) Clinical activity score (CAS) reduction to 0 or 15 54% 24% p = 0.0060 CAS mean change from baseline5 -2.9 -1.3 p < 0.0001
Page 44
-0.62 -0.72 -0.69 -0.75 -0.46 -1.06 -1.70 -2.04 -2.22 -2.34 -3 -2 -1 0 0 20 40 60 80 100 44 Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from prespecified, exploratory endpoint analyses. Statistically significant proptosis responder rate at all time points, including at 3 weeks, after just one infusion of veligrotug Rapid and statistically significant proptosis responder rate at 3 weeks, after just 1 infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline Proptosis Responder Rate (%)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Proptosis Mean Reduction (mm)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Analysis Visits Placebo Veligrotug Analysis Visits Placebo Veligrotug 10% 25% 13% 40% 11% 50% 13% 54% 8% 56%
Page 45
0 20 40 60 80 100 0 20 40 60 80 100 Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from prespecified, exploratory endpoint analyses. TED = thyroid eye disease. 45 THRIVE-2 is the first phase 3 study in patients with chronic TED to demonstrate statistically significant diplopia response & resolution Diplopia Responder Rate Diplopia Complete Resolution Diplopia Responder Rate (%)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Analysis Visits Placebo Veligrotug Diplopia Resolution Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Analysis Visits Placebo Veligrotug 22% 29% 14% 47% 24% 52% 19% 55% 25% 56% 14% 18% 5% 31% 11% 36% 11% 33% 14% 32%
Page 46
46 Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Study eye is defined as eye with greater proptosis at baseline, as measured by corresponding measurement modality (i.e., Hertel study eye for Hertel endpoints, and MRI / CT study eye for MRI / CT endpoints). CT = computed tomography, mm = millimeter, MRI = magnetic resonance imaging. THRIVE-2 demonstrated consistency between Hertel exophthalmometry and MRI / CT as measurements of proptosis THRIVE-2 demonstrated both exophthalmometry and MRI / CT are reliable tools for measurement of proptosis, building on data from THRIVE Hertel exophthalmometry MRI / CT Veligrotug (n=125) Placebo (n=63) Proptosis responder rate at week 15 56% 8% Proptosis mean change from baseline at week 15 -2.34 mm -0.46 mm Veligrotug (n=125) Placebo (n=63) Proptosis responder rate at week 15 48% 3% Proptosis mean change from baseline at week 15 -2.07 mm -0.36 mm
Page 47
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). 1 3 SAEs in 3 participants: Grade 3 vertigo (related), Grade 2 arthralgia (unrelated), Grade 2 metabolic encephalopathy (unrelated); 2 2 SAEs in 2 participants: Grade 3 urticaria (related), Grade 3 fatigue (unrelated). AE = adverse event, SAE = serious adverse event, TEAE = treatment-emergent adverse event. 47 Veligrotug was generally well-tolerated, and 94% of veligrotug-treated patients completed their treatment course Veligrotug N=125 n (%) Placebo N=63 n (%) Participants with any treatment-emergent adverse event (TEAE) 106 (85%) 43 (68%) Participants with any serious AE (SAE) 3 (2%)1 2 (3%)2 Participants with any treatment-related TEAE 79 (63%) 14 (22%) Participants with any treatment-related SAE 1 (1%)1 1 (2%)2 • Vast majority of TEAEs in both arms were mild • Low treatment discontinuation rate ‒ 6% in veligrotug arm
Page 48
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). 1 Terms aggregated utilizing methodology used by FDA for approved products for treatment of thyroid eye disease, 2 Reported as percentage of menstruating women. AE = adverse event. 48 Veligrotug was generally well-tolerated, with a 9.6% placebo-adjusted rate of hearing impairment AEs AEs occurring at ≥10% frequency in either arm Veligrotug N=125 n (%) Placebo N=63 n (%) Muscle spasms 45 (36%) 4 (6%) Headache 18 (14%) 8 (13%) Hearing impairment1 16 (13%) 2 (3%) Fatigue1 15 (12%) 5 (8%) Diarrhea 14 (11%) 6 (10%) Hyperglycaemia1 13 (10%) 3 (5%) Menstrual Disorders1,2 16 / 48 (33%) 2 / 20 (10%)
Page 49
49 Elegrobart (VRDN-003) Phase 1 Data
Page 50
Source: Preliminary Viridian clinical data on file as of April 12, 2024 data cut. Multi-dose cohort was a 600 mg loading dose followed by a 300 mg second dose at day 28. Six participants were dosed in each of the single-dose elegrobart cohorts, and four participants were dosed in the multi-dose cohort. IGF-1 = insulin-like growth factor 1, HV = healthy volunteers, PD = pharmacodynamics, PK = pharmacokinetics, SC = subcutaneous. 50 Phase 1 HV Study: Subcutaneous elegrobart showed an extended half-life of 40–50 days and sustained IGF-1 levels after dosing Elegrobart half-life is 40–50 days Elegrobart increases IGF-1 levels ~4-fold 0 50 100 150 0.1 1 10 100 Time (Days) Drug Concentration (μg/mL) VRDN-003 SC (300 mg single dose) VRDN-003 SC (600 mg single dose) VRDN-003 SC (600 mg + 300 mg multi-dose) 0 50 100 150 0 2 4 6 Time (Days) Fold Change from Baseline IGF-1 VRDN-003 SC (300 mg single dose) Placebo VRDN-003 SC (600 mg single dose) VRDN-003 SC (600 mg + 300 mg multi-dose) PK / PD updated with multi-dose cohort Phase 1 HV Pharmacokinetics (PK) Phase 1 HV Pharmacodynamics (PD)
Page 51
• No hearing-related AEs • No treatment-related discontinuations • All elegrobart related AEs were Grade 1 (mild), no SAEs • All treatment-related AEs resolved during follow-up 1 Injection Site Reactions and Hearing Impairment each includes multiple MedDRA terms. Source: Preliminary Viridian clinical data on file as of April 12, 2024 data cut. ADA = anti-drug antibodies, AE = adverse event, HV = healthy volunteer, ISRs = Injection Site Reaction, MedDRA = Medical Dictionary for Regulatory Activities, SAE = serious adverse event, SC = subcutaneous. 51 Phase 1 HV Study: Subcutaneous elegrobart was well-tolerated Elegrobart Single Dose SC (n = 12) Two Doses SC (n = 4) Placebo (n = 6) All Observed AEs 9 (n = 3) 2 (n = 2) 2 (n = 2) AEs deemed to be related to elegrobart 3 1 -- Injection Site Reactions (ISRs)1 1 (8%) -- -- Muscle Spasms -- -- -- Hyperglycemia -- 1 (25%) -- Hearing Impairment1 -- -- -- Insomnia 1 (8%) -- -- Hepatic Enzyme Increase 1 (8%) -- -- Severe Adverse Events (SAEs) -- -- 1 (16.7%) # Grade 3/4 AEs -- -- 1 (16.7%) # Anti-Drug Antibodies (ADAs) Low ADAs detected after Day 71 # One participant in the placebo arm was diagnosed with stage 4 lung cancer, which was considered both a SAE and a Grade 3/4 AE. The participant subsequently withdrew from the study.
Page 52
52 FcRn Non-Human Primate Data
Page 53
Non-human primates (NHPs) were dosed with IV bolus of 20 mg/kg VRDN-006, 20 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle every 4 days for 4 doses. Source: Viridian data on file. IgG = Immunoglobulin G, IV = intravenous, NHP = non-human primate, PK= pharmacokinetics, WT Fc = wild type neonatal fragment. 53 VRDN-006 in vitro, multi-dose NHP PK and IgG reduction data compared to efgartigimod pH-Dependent Binding Internal Target Occupancy 0.01 0.1 1 10 100 1000 10000 0 1×106 2×106 3×106 Concentration (nM) Mean Flourescence Intensity Efgartigimod WT Fc Control VRDN-006 0.0001 0.001 0.01 0.1 1 10 100 1000 0 1×105 2×105 3×105 4×105 Concentration (nM) Mean Flourescence Intensity WT Fc Control Efgartigimod VRDN-006 pH 7.4 pH 6 Multi-Dose NHP Pharmacokinetics 0 5 10 15 20 25 1 10 100 1000 Time (Days) Serum Concentration [μg/mL] VRDN-006 (20 mg/kg, IV) Efgartigimod (20 mg/kg, IV) Dose 0 5 10 15 20 25 0 50 100 150 Time (Days) IgG Response (%) Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV) Vehicle Dose v Multi-Dose NHP Pharmacodynamics
Page 54
VRDN-006 Spares Albumin VRDN-006 Spares LDL Non-human primates (NHPs) were dosed with IV bolus of 20 mg/kg VRDN-006, 20 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle every 4 days for 4 doses. Source: Viridian data on file. CFB = change from baseline, IV = intravenous, LDL = low-density lipoprotein, NHP = non-human primate. 54 VRDN-006 spares albumin and LDL in multi-dose NHP study 0 5 10 15 20 25 0 50 100 150 200 Time (Days) CFB Concentrations (%) Vehicle Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV) Dose 0 5 10 15 20 25 0 50 100 150 Time (Days) CFB Concentrations (%) Vehicle Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV)Dose v
Page 55
VRDN-008 Showed ~3x Longer Half-life Head-to-Head vs. Efgartigimod in NHPs VRDN-008 Showed ~20% Deeper and More Sustained IgG Reduction Head-to-Head vs. Efgartigimod in NHPs v Non-human primates (NHPs) were given equimolar doses of 60 mg/kg VRDN-008, 48.5 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle - all via IV bolus. Source: Viridian data on file. BLQ = below limit of quantification, IgG = Immunoglobulin G, IV = intravenous, NHP = non-human primate. 55 A single dose of VRDN-008 demonstrated a longer half-life, deeper and more sustained reduction of IgG vs. efgartigimod 0 7 14 21 28 35 42 0.01 1 100 10000 Time (Days) Concentration (μg/ml) VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) 0 7 14 21 28 35 42 0 25 50 75 100 125 150 Time (Days) IgG Concentration Mean % Change from Baseline VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle Efgartigimod levels were BLQ at Days 35 and 42
Page 56
VRDN-008 Spares Albumin VRDN-008 Spares LDL 0 7 14 21 28 35 42 50 75 100 125 Time (Days) Albumin Concentration Mean % Change from Baseline VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle 0 7 14 21 28 35 42 50 100 150 Time (Days) LDL Concentration Mean % Change from Baseline VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle Non-human primates (NHPs) were given equimolar doses of 60 mg/kg VRDN-008, 48.5 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle - all via IV bolus. Source: Viridian data on file. IV = intravenous, LDL = low-density lipoprotein, NHPs = non-human primates. 56 A single dose of VRDN-008 spares albumin and LDL in NHPs v